Streetbeat News

PYPD

PolyPid Ltd.

https://www.polypid.com

Industry

Biotechnology

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Open

3.56

Mkt cap

24M

Volume

3K

High

3.62

P/E Ratio

-0.50

52-wk high

9.20

Low

3.55

Div yield

N/A

52-wk low

2.95

Polypid has filed for an ordinary shares offering of up to $200 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:09 pm

PolyPid provides an update on its SHIELD II trial, which aims to address the rising rates of surgical site infections (SSIs) post-COVID. With 250 out of 600 patients enrolled, an unblinded interim analysis will be conducted after 400 patients complete their 30-day follow-up. Top-line results are expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

HC Wainwright & Co. has reiterated its Buy rating on PolyPid (NASDAQ:PYPD) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 10:16 am

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on PolyPid (NASDAQ:PYPD) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:23 am

PolyPid (NASDAQ:PYPD) reported Q1 2024 GAAP EPS of $(1.37), surpassing the $(1.58) analyst consensus estimate by 13.29%. This marks an 83.83% improvement over the previous year's $(8.47) per share loss.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:05 am

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on PolyPid (NASDAQ:PYPD) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:27 am

Rosalind Advisors, Inc. has reported a 9.95% stake in PolyPid Ltd. as of February 13, 2024, according to a 13G filing with the SEC.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 5:53 pm

PolyPid (NASDAQ:PYPD) reported a Q4 EPS loss of $(3.97), missing the consensus estimate of $(3.58) by 10.89%. However, this represents a 58.65% improvement over the previous year's loss of $(9.60) per share.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 12:11 pm

Earnings reports for various companies are scheduled for February 14, 2024. The report includes projections for earnings per share and revenue for a wide range of companies across different sectors, including technology, healthcare, industrial, consumer goods, and financial services. Some companies are expected to report losses, while others anticipate profits.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 9:48 am

Applied Therapeutics, Inc. (NASDAQ:APLT) shares plummeted by over 35% after announcing topline results from the ARISE-HF Phase 3 trial of AT-001, which did not meet its primary endpoint. Other stocks experienced significant movement in Friday's mid-day session, with various companies reporting gains due to positive updates, acquisitions, and earnings, while some faced declines due to negative guidance, downgrades, and public offerings.

Portfolio Pulse from Avi Kapoor

January 05, 2024 | 6:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.